Allergan Aesthetics highlights skin longevity and exosome research at 2026 Science of Skin Summit

Allergan Aesthetics, an AbbVie company, will present new scientific discussions around skin longevity, ageing biology and emerging exosome research at the 2026 Science of Skin Summit in Austin, Texas.

The event, taking place from 17 to 20 September, will feature experts from the company’s research and development teams discussing the biological processes involved in ageing and how stronger scientific evidence can support innovation in skincare and regenerative aesthetics.

A key part of Allergan Aesthetics’ programme will focus on exosome based skincare technologies, an area attracting increasing interest as regenerative approaches continue to expand within aesthetics.

SkinMedica, part of Allergan Aesthetics, will introduce its FACTS Principles during the summit. The framework is designed to promote a more consistent scientific approach to evaluating exosome based skincare products.

FACTS focuses on five areas: formulation and stability of the final product, analysis, clinical studies, the type of cellular origin used and safety.

Prithwiraj Maitra, PhD, Vice President of Skincare Research and Development at Allergan Aesthetics, said technologies involving growth factors and exosomes represent an emerging area of skincare research, but progress needs to be supported by scientific transparency.

He said evaluating a product requires more than reviewing its ingredient list, with researchers also needing to determine whether biological activity remains stable and effective in the final formulation.

Allergan Aesthetics said the FACTS Principles are intended to encourage more consistent and evidence based discussion across the rapidly developing exosome skincare category.

The company is also focusing on how exosome technologies are sourced, formulated, preserved and studied as interest in regenerative aesthetics continues to grow.

Allergan Aesthetics said its approach is supported by more than 25 years of skincare research, over 200 clinical studies, numerous U.S. patents covering skincare technologies and advanced formulations, and 100 peer reviewed publications.

The company will use this experience to contribute to wider discussions at the summit about how biological ageing influences skin health and how emerging scientific findings could shape future skincare development.

Stephanie Manson Brown, MD, Vice President and Head of Clinical Development, Scientific Innovation and Skincare Research and Development at Allergan Aesthetics, said future skincare innovation will increasingly depend on understanding the biological systems that support healthy skin over time.

She added that improving knowledge of the hallmarks of ageing and their relationship with skin biology could help researchers develop products that address outcomes important to both healthcare professionals and consumers.

---

---

Related Topics and Keywords

AbbVie, aesthetic medicine, ageing biology, Allergen, dermatology, exosomes, pharma news